Get started

Biotech

EYPT EyePoint Pharmaceutics LONGEYPT is now on another breakout on the 2h chart similar to what occurred from mid-December to mid-January. On the indicators the MACD shows the K/D lines on a steep upward slope. For me, what set off my interest was a relative volume scan that produced this stock on the list. The relative volume this week and consequential accumulation triggered the breakout with those volume spikes Fundamentally, EYPT had a catalyst as it completed one phase of its FDA clinical trials for a treatment for macular degeneration, a debilitating eye disease of the elderly. The potential market is several multiples of the stock's current market cap. This company is a takeover candidate as it is young without a big pipeline but with upside potential. The relative volume of 4X to 8X is a sure sign that buying pressure will move the price. Price has crossed the SMA50 just as it did last winter. The price is up 40% or more this week. Could this be a pump and dump? Maybe. For sure it is a speculation play just like many NASDAQ penny biotech stocks For mem the price action of last winter with a 120% gain in one month is reassurance for this time around with some hopeium thrown into the mix with the technical analysis. I will buy a call option under the current price with the 4/21 expiration and leverage the speculation a bit. In the past day, this option rose 67% based on the price surge of the underlying stock.
NASDAQ:EYPTLong
by AwesomeAvani
3
Harvard Bioscience: Bouncing Higher From Multiple-Year SupportI zoomed all the way out to the monthly chart to show the long-term support levels. We can see that HBIO is bouncing higher from a multi-year support level in the $2 range. The MACD (middle of the chart) didn't confirm an upward trend yet. However, the MACD did confirm the upward trend on the weekly chart. It looks like the blue monthly MACD line is close to crossing above the red signal line. The purple RSI line on the bottom of the chart is pointing upward, which is bullish. This indicates that we could see a long-term continuation of the rally which began in December/January. Click on the link below for a detailed article. HBIO has a low valuation with strong expected EPS growth. This is likely to drive the stock higher IMO.
NASDAQ:HBIOLong
by Zman1175
$SAGE: strong base, upcoming catalysts$SAGE is an interesting stock here, has pending catalysts for mid 2023, which fit the expectations from the Time@Mode technical pattern at hand here. Consider the volatility of these biotech names when entering, stock could move huge after data comes out (up or down) but odds are good that it breaks to the upside given the technical pattern suggesting the smart money has been accumulating stock. Upcoming catalysts: SAGE-217 - (SHORELINE) Major Depressive Disorder (MDD) Phase 3 additional data due in mid-2023. Zuranolone (SAGE-217) Major depressive disorder (MDD) and Postpartum Depression PDUFA priority review date of August 5, 2023. Best of luck! Cheers, Ivan Labrie.
NASDAQ:SAGELong
by IvanLabrie
1
The Future of Crypto MarketCap: TA to Navigating the 2030 AgendaGreetings fellow traders and investors, The world events of the past year have had a profound impact on the global economy, and the crypto market has not been immune to these effects. As we move forward into the next period of capitalization, it is important to take a closer look at the current state of the crypto market and how it may be affected by the events unfolding around us. In this analysis, I will examine some of the key factors that are likely to shape the crypto market in the coming months, including the ongoing COVID-19 pandemic, geopolitical tensions, and the transition to a digital economy. I will also explore some of the potential opportunities and challenges that traders and investors may encounter in this dynamic and rapidly evolving landscape. Whether you are a seasoned trader or a newcomer to the crypto market, I believe that this analysis will provide you with valuable insights and actionable strategies for navigating the challenges and opportunities of the next capitalization period. So join me as we explore the future of the crypto market together, and let's uncover the hidden gems and potential profits that lie ahead. Thank you for your attention, and let's get started! We established great support at 750B, distribution was set, and we are now in an uptrend. This may be short lived after the events around us unfolding. The reactions of these events unfold slowly but will have a massive impact on the way we live. It's no secret that this is modern warfare. There is a lot of uncertainty with our global currency, the USD. From it not becoming the figure of value of the Saudi Oil Barrel to China leaping into taking the throne. It won't be long before news arouses over the "printing" of dollars from other countries such as Venezuela that they have officially figured out how to perfectly replicate it. This is pure speculation by the way. But it will play out. Banks will have "outages" which could last up to 3 days. Once that is survived, we may be presented with digitalizing the USD, and other world currencies. How will this play out? Well, I am not Cryptodamous. But I will pretend that I am. Uptrend: | Ends May 2023 | The speculation of uncertainty with the USD, people "Preparing" etc. will cause the market to go back to 1.5T, this will be short lived, and this is where the media will cover it, everyone will start to buy in again. This is your indicator to sell. Downtrend: | May 2023 - Nov. 2023 | Within 33 days, a new plannedemic will start to become mainstream. What is it, not sure... Could be Anthrax. If it's Anthrax, well it will start off with Animals being infected by polluted soil and water. What can cause this? Of course, not train derailments leaking into our soil and rivers that interconnect with all major water sources for our (US) farmland. But we will be blamed for our carbon footprint. The collateral damage will be a worldwide event. Food shortages, more control and possibly the first ever worldwide internet shortage. If what we are ingesting is infected, well then, we are also infected. All water above ground will be vulnerable. (Advice to buy land that you can tap a water well into) This will last for 6-8 months. This will correct the market into what everyone was expecting. $12k BTC. (The potential to Flash wick into $7k exists - this will only last 2 hours). Overall, this will place the total crypto market cap at $565B The new Bull Cycle: | Nov. 2023 - Dec. 2025 | The introduction to a new form of control. Digitalizing the US dollar. The people will catch up to this soon as they come to realization that you have 0 privacy. Your money expires. All your whereabouts will be monitored. But most importantly, taxing our carbon footprint. We are the first generation of humans to live life like this. This is new to everyone and although we can look at the past for the rise and fall of nations, we have the technology to break out of this system and treat Bitcoin as the true Digital "Gold." All the above is not trading advice. Use TA to accurately make your trading decisions. Freedom doesn't have a price. But if it did, it's not worth less than 10 Trillion :) and people will pay 100 Trillion :)
CRYPTOCAP:TOTAL
by jovani7919
MRNA | This is a BUY | BOUNCEModerna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by DivergenceSeeker
3
Young biotech leader $IMCR with good VCPImmunocore Holdings is a commercial-stage T cell receptor biotechnology company working to develop and commercialize transformative medicines for oncology, infectious diseases and autoimmune and inflammation diseases. In a confirmed uptrend, yesterday signaled a good pivot buy where I placed an initial position. I liked the volatility contraction pattern and the bullish divergence with the 10-day ROC prior to the breakout, and now I'll wait for the follow through action to add to the position. Lets wait and see.
NASDAQ:IMCRLong
by dpuleo19
BZYR: Potential long term investment - with riskI've become interested in BZYR which trades only OTC at this time. Why is this OTC stock of high importance for long term investors? In order to set this out my post is broken into various parts: 1 - Introduction 2 - The historical battles 3 - Efficacy of a cancer treatment 4 - Summary 5 - The risk to reward for long term investors. The above cannot possibly avoid referring to organisations and materials in the public domain - as matters of fact and truth before the courts. Introduction: The founder has discovered a treatment for cancers that cannot be treated by conventional treatments, that is better than anything out there at this time. The research has been in the public domain for the last 30-odd years. The discovery is called Antineoplastons - which is a combination of various peptides and other 'chemicals'. Historical battles: The research evidence for efficacy has not been faulted. The FDA (in the public domain) took the founder through 4 grand juries. The case failed at the Texas State Supreme Court, in an attempt to remove the founder's medical licence. The whole story runs very deep back to the 1980s - but despite strenous efforts to shut down the treatment (and the founder), it persists to this day, through the endless legal battles. Staying within the 'House Rules' means that I am cautious not to breach. In 1982 the FDA stated " never have and never will approve a new drug to an individual but only to a large pharmaceutical firm with unlimited finances ." Therefrom sprung one of the most severe fights in FDA history. dealings with the FDA commenced in 1983 at that point the FDA commenced a civil action to try to close the clinic and stop all patients from receiving the medicine before the judge in this case. Before the judge in the 1983 court case had announced her ruling the FDA sends her a letter warning her in advance " if this court declines to grant the injunction sought by the government thus permitting continued manufacture and distribution of antineoplastons the government would then be obliged to pursue other less efficient remedies such as actions for seizure and condemnation of the drugs or criminal prosecution of individuals. " Efficacy of cancer treatment with Antineoplastons: Mainstream cancer research organisations will say " There is not enough reliable evidence to use it as a cancer treatment " or that the treatment is ' experimental '. But this is not true. If there has been an experiment, it was fully under the watch of the FDA, and the results are beyond belief for success. Double-blind randomised controlled trials in Japan have proved the superior efficacy of the treatment (which is not 100% but far better than what exists). Summary Antineoplaston treatment has weathered all battles for over 30 years. It's not going away. It's survival suggests something novel and unique has been discovered. Why is this treatment surviving at all? Why all the battles against it? Those are matters for you to ponder. The risk to reward for long term investors: The weeky chart will show that BZYR (an OTC stock) is near rock bottom and possibly in an accummulation phase. Note carefully that OTC stocks are not on conventional exchanges like NYSE and NASDAQ. The potential growth over a 5 year period could be significant in relation to a fixed risk of loss which should be an affordable one, if more research confirms it's specific kind of efficacy. This could be the next 'Amazon' of the biomedical world. As always I emphasise the risk - and I am unable to provide tips on how to manage that. Disclaimers apply.
OTC:BZYR
by Captain_Walker